US- based IQVIA has announced its collaboration with AstraZeneca to accelerate development of a potential new vaccine for Covid-19. This joint initiative is part of the US government’s recently announced operation warp speed project.
Operation warp speed is part of a broader strategy to accelerate the development, manufacturing, and distribution of Covid-19 vaccines, therapeutics, and diagnostics. The specific IQVIA and AstraZeneca collaboration will drive faster delivery of clinical studies in the US to demonstrate the efficacy of AstraZeneca’s potential Covid-19 vaccine, AZD1222. This initiative includes an expansive subject study, which is expected to begin enrolling participants this summer and leverage IQVIA’s virtual trial solutions, including study hub.
IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE, IQVIA claims to deliver unique and actionable insights at the intersection of large-scale analytics, transformative technology, and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries, including India.